Loading...
NPI 1710367982 · Hattiesburg, MS · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Eagle Labs 1 is a clinical medical laboratory provider located in Hattiesburg, Mississippi. This profile covers 12 Medicare and 4 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Eagle Labs 1 |
| Address | 4 Willow Pointe |
| City | Hattiesburg |
| State | MS |
| ZIP | 39402 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | June 3, 2015 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $1.6M |
| Medicaid | $1.3M |
EAGLE LABS 1 operates as a clinical medical laboratory with an operational profile heavily weighted toward drug testing and amplified nucleic acid infectious-agent assays. Its top Medicare codes are dominated by definitive drug testing (G0483) and presumptive drug screening (80307) alongside an amplified nucleic acid code for unspecified infectious agents (87798), which together reflect lab capacity for GC/MS or LC/MS confirmatory testing plus high-volume instrumented screening and NAAT workflows.
Medicare revenue is concentrated: the practice reported $1.6M in total Medicare revenue and its top three Medicare codes account for 84.6% of that payer’s revenue. Those top Medicare contributors are G0483 (43.3% of Medicare revenue, $675.4K), 87798 (30.0% of Medicare revenue, $467.8K), and 80307 (11.2% of Medicare revenue, $175K), indicating a narrow set of high-yield services driving most Medicare billing.
Medicaid billing is even more concentrated around drug testing: the provider reported $1.3M in total Medicaid revenue with the top three Medicaid codes accounting for 98.5% of Medicaid revenue. G0483 is the dominant Medicaid driver (71.2% of Medicaid revenue, $939.7K), followed by 80307 (23.4% of Medicaid revenue, $309.3K) and G0481 (3.9% of Medicaid revenue, $51.7K), signaling that definitive and presumptive drug tests overwhelmingly represent the provider’s Medicaid footprint.
The provider’s payer mix is essentially dual but near-parity in scale: Medicare is $1.6M versus Medicaid $1.3M, so EAGLE LABS 1 is not single-payer dependent and shows meaningful business from both Medicare and Medicaid populations. This near-equal scale suggests operational capacity sized to serve multiple payer channels rather than a focus on only one program.
National competitive standing on Medicare shows elevated percentiles for key codes but the dataset labels those volumes as typical for many labs: G0483 ranks #34 of 1063 (97th percentile; typical, unremarkable volume), 87798 ranks #116 of 1319 (91th percentile; typical, unremarkable volume), and 80307 ranks #80 of 4760 (98th percentile; typical, unremarkable volume). These positions indicate the provider is a substantial national participant on these specific services, though the characterization provided describes the volumes as within a common range for laboratories that offer these tests.
In-state competitive standing on Medicaid is markedly different: G0483 ranks #1 of 24 in-state (100th percentile; extreme outlier, far above typical state volume), establishing EAGLE LABS 1 as a dominant provider of definitive drug testing in Mississippi. 80307 also ranks highly in-state at #8 of 118 (94th percentile; notably above typical state volume), reinforcing a strong regional market position for both definitive and presumptive drug testing services.
The code mix and payment-adjudicated averages imply a high-throughput toxicology operation with confirmed-specimen workflows: the prominence of G0483 (definitive testing with extensive drug classes and specimen validity testing) together with large volumes reported for 80307 (instrumented presumptive screens) indicates significant specimen-processing capacity and investment in confirmatory instrumentation and quality-control processes. This suggests the lab is structured to receive and process large specimen volumes rather than focusing primarily on low-throughput, specialized molecular diagnostics.
EAGLE LABS 1 has been enumerated since 2015-06-03 (~11 years ago), providing about a decade of presence in claims data. Combined with concentrated, high-volume billing in both Medicare and Medicaid, the tenure supports an established business rather than a short-lived or nascent operation.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
12 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2,790 | $240 | $675.4K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 13,760 | $30 | $467.8K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 2,870 | $60 | $175K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 2,650 | $30 | $89.9K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 1,040 | $30 | $35.4K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 1,040 | $30 | $35.4K |
| 87511 | The lab analyst performs a test for Gardnerella vaginalis using amplified nucleic acid probe technique. Gardnerella vaginalis, typically causes bacterial vaginosis, an infection of the vagina that… | 800 | $30 | $27K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 530 | $30 | $18.1K |
| 87641 | The lab analyst performs a test for methicillin–resistant Staphylococcus aureus (MRSA) using an amplified nucleic acid probe technique. | 530 | $30 | $18.1K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 190 | $70 | $13.1K |
Showing 1–10 of 12
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 12 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
4 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 8,620 | $110 | $939.7K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 11,050 | $30 | $309.3K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,010 | $50 | $51.7K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 200 | $100 | $19.8K |
How this provider's Medicaid billing volume and revenue compare to other Mississippi providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Mississippi median
4 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 8 | 120 | 1,650 | $30 | $115K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 20 | 370 | $100 | $114.2K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 13 | 20 | 420 | $60 | $61.7K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 8 | 30 | 540 | $60 | $49.9K |
Other providers in the same ZIP code as Eagle Labs 1, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.